Letter: Biological drugs for inducing remission in ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 10, 2014, Pages 1242-1244

  Maratea, D ^a   Fadda, V ^a   Trippoli, S ^a   Gatto, R ^a   De Rosa, M ^b   Marinai, C ^a   Messori, A ^a  

^a ESTAV Toscana Centro   (Italy)

^b Italian Society of Clinical Pharmacy and Therapeutics   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT;

CLINICAL RESEARCH; CLINICAL STUDY; COMPARATIVE STUDY; DATA ANALYSIS; LETTER; PRIORITY JOURNAL; REMISSION; RISK FACTOR; STATISTICAL ANALYSIS; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898903240     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12690     Document Type: Letter

References (10)

1. Ahn S, Park SH, Lee KH,. How to demonstrate similarity by using noninferiority and equivalence statistical testing in radiology research. Radiology 2013; 267: 328-38.
2. Messori A, Fadda V, Maratea D, Trippoli S,. Outcomes with short-term versus long-term antiplatelet dual therapy after drug-eluting stenting: quantifying the equivalence margins. Int J Cardiol 2014; 172: 469-70.
3. Messori A, Maratea D, Fadda V, Trippoli S,. Risk of intracranial haemorrhage in patients with atrial fibrillation treated with novel oral anticoagulants: testing the equivalence margins between dabigratran, rivaroxaban and apixaban. Eur J Clin Pharmacol 2014; 70: 505-6.
4. Messori A, Fadda V, Maratea D, Trippoli S,. Rates of inhibitor development in previously untreated patients with severe haemophilia A treated with plasma-derived or recombinant Factor VIII: no proof of difference or proof of no difference? Semin Thromb Hemost 2014; 40: 269-70.
5. Stidham RW, Lee TC, Higgins PD, et al,. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2014; 39: 660-71.
6. Messori A, Fadda V, Gatto R, Maratea D, Trippoli S,. PubMed Commons (comment). Available at: http://www.ncbi.nlm.nih.gov/pubmed/24506179. Accessed February 12, 2014.
7. Reinisch W, Sandborn WJ, Hommes DW, et al,. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-7.
8. Norman G, Monteiro S, Salama S,. Sample size calculations: should the emperor's clothes be off the peg or made to measure? BMJ 2012; 23: e5278.
9. Fadda V, Maratea D, Trippoli S, Messori A,. Network meta-analysis. Results can be summarised in a simple figure. BMJ 2011; 23: d1555.
10. Bucher HC, Guyatt GH, Griffith LE, Walter SD,. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-91.